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Abstract
Background—Lung cancer is the most common cause of cancer-related mortality. Smoking
cessation is crucial to decrease risk but additional prevention modalities are needed. Use of non-
steroidal anti-inflammatory drugs (NSAIDs) may be promising.
Methods—The study was a prospective cohort of 77,125 men and women aged 50–76 years from
Washington State recruited in 2000–2002 (the VITAL study). Lung cancer cases were identified
through the Seattle-Puget Sound SEER cancer registry during 5 years of follow-up. Hazard ratios
(HRs) associated with 10 year average use of total NSAIDs (excluding low-dose aspirin) and specific
categories of NSAIDs were calculated for total incident lung cancer and specific morphologies.
Results—665 lung cancer cases were identified. After adjusting for smoking, age, gender, and
acetaminophen use, there was a borderline-significant inverse trend with total NSAID use (>4.2 days/
week over 10 years vs. none, HR 0.82, 95% CI, 0.64–1.04, P for trend 0.05). The association was
strongest for adenocarcinoma (HR 0.59, 95% CI, 0.37–0.94, P for trend 0.01) and appeared to be
limited to men (HR 0.66, 95% CI, 0.47–0.92, P for trend 0.01) and to long-term (≥ 10 years) former
smokers (HR 0.65, 95% CI, 0.44–0.96, P for trend 0.04). There were no appreciable differences by
NSAID type.
Conclusions—Total NSAID use was associated with a small reduced risk of lung cancer which
was strongest for adenocarcinoma, men, and long-term former smokers. These findings are supported
by known lung carcinogenesis mechanisms, and suggest that NSAIDS may be useful for
chemoprevention.
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INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality in the United States (US) (1).
Smoking cessation is very important to reduce the risk of developing lung cancer but absolute
risk remains elevated after cessation (2), emphasizing the importance of additional prevention
modalities.
The cyclooxygenase 2 (COX-2) pathway is important in the pathogenesis of lung cancer,
particularly adenocarcinoma (3–6). Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit
the COX-2 enzyme and may reduce the incidence of lung cancer through several mechanisms
(7–9). A meta-analysis indicated a lower risk of incident lung cancer in NSAID users with a
relative risk of 0.79 (95% CI, 0.66–0.95) and dose-response analyses found longer term use
seemed to be more strongly associated with a decreased risk (10).
We used data from a large prospective cohort, the VITamin And Lifestyle (VITAL) study
(11) to evaluate associations of 10 year average use of NSAIDs with incident lung cancer.
METHODS
The methods employed in VITAL have been described (11). 77, 719 participants (21.3% of
the total number of mailed questionnaires), aged 50–76 years, living in Western Washington
State, were followed after baseline questionnaire administration for incident lung cancer
occurring from baseline (October 2000–December 2002) through December 31, 2006, by
linkage to the Seattle-Puget Sound Surveillance, Epidemiology, and End Results (SEER)
registry. The Institutional Review Board of the Fred Hutchinson Cancer Research Center
approved the protocol.
Participants with a self-reported previous diagnosis of lung cancer or for whom this datum was
missing (n= 588), with lung cancer identified on a death certificate only (n = 4), or lung cancer
morphology of lymphoma (n=2) were excluded. The censored date was the earliest date of
withdrawal from the study (0.03%), death (3.9%) (ascertained from Washington state death
files), move out of the SEER catchment area (5.4%), or last date of linkage to SEER. If a subject
had multiple diagnoses of lung cancer, we used the time to first diagnosis.
Assessment of NSAID use
Respondents reported their use of regular or extra-strength aspirin, low-dose aspirin, ibuprofen,
naproxen, celecoxib or rofecoxib, and acetaminophen (listed as generic and brand names)
during the ten years prior to baseline. Women also reported the use of indomethacin and
piroxicam. Subjects reported how many years they used each medication in the previous ten
years (1–3, 4–8 or 9–10 years) and the usual number of days per week. (1–3, 4–6 or 7). For
the analysis, we estimated total average use over the 10 years by multiplying usual days per
week by the number of years, using the midpoints of the categories, divided by 10. Total NSAID
use was estimated by summing average weekly use of all NSAIDs, except low-dose aspirin.
Secondary analyses evaluated total non-aspirin NSAID use (all NSAIDs as above except
regular/extra strength and low-dose aspirin), total aspirin use (excluding low-dose aspirin), and
each NSAID individually.
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Tobacco—We adjusted all the analyses for multiple smoking variables as previously
described (12)
Additional covariates—Demographic, socioeconomic factors, previous history of cancer
and self-report of physician-diagnosed emphysema or chronic obstructive pulmonary disease
(COPD) were recorded. We categorized family history of lung cancer as none or at least one
first degree relative with lung cancer. Indications for NSAID use included self-report of a
physician diagnosis of arthritis (rheumatoid and/or osteoarthritis), coronary artery disease
(computed as a history of coronary artery bypass graft, angioplasty, angina, and/or “heart
attack”), chronic pain, and/or chronic headaches.
Statistical Analysis
All statistical analyses were performed using Stata SE-9 (StataCorp, College Station, TX). Cox
regression was used to estimate the hazard ratios (HR) for associations of NSAID use categories
with incident lung cancer, with robust standard errors to eliminate traditional proportional
hazards assumptions. Age was the time variable, with left truncation for age at baseline and
censoring. Subjects with missing data on NSAID use or other covariates in the model were
excluded from analysis. NSAID use was analyzed by categories of use and as indicator
variables, to estimate hazard ratios for lung cancer. We categorized the exposures into four
groups: never use and tertiles of use based on the distribution in the entire cohort. Only 5.1%
of subjects reported celecoxib/rofecoxib use so we created a dichotomous variable of use and
no use. We treated the NSAID use categories as a continuous variable to assess for trends in
lung cancer risk.
Based on previous work, we used a model to adjust for confounding by cigarette smoking that
included years smoked, pack-years, and a squared pack-years term along with age and gender
(12). We adjusted regular aspirin use for non-aspirin NSAID use and vice versa. We evaluated
whether education, acetaminophen use (which shares NSAID indications), COPD, previous
history of cancer, family history of lung cancer, arthritis, coronary artery disease, chronic pain,
and/or chronic headaches confounded the association of total NSAID use with lung cancer.
Except for acetaminophen use, no variables changed the point estimates by ≥ 10% or level of
statistical significance for total NSAID; thus, only acetaminophen use was added to the model.
We examined whether the associations for NSAID use differed by lung cancer morphology by
treating each morphology as a separate outcome, exclusive of the other morphologies,
compared to subjects who did not develop lung cancer. We also looked for differences of the
NSAID-lung cancer associations defined by smoking status and sex. Likelihood ratio tests
were conducted to assess the interaction between NSAID use, analyzed as trend variables, and
the subgroups. P values for interaction were obtained to compare the fit of the models with the
interaction terms and without them. P values less than 0.05 were considered statistically
significant.
Funding Source
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to E.W., and CA96556 and CA119683 to J.S.]. The sponsors had no role in the conduct of the
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77,125 subjects met inclusion criteria and were followed for a mean of 5.0 years (SD 1.01
years); 665 subjects developed lung cancer. Frequent use of total NSAIDs was associated with
a borderline trend of reduced incidence of lung cancer (Table 1). Non-aspirin NSAIDs and
regular aspirin use were each associated with a non-significant decreased lung cancer risk. Use
of low-dose aspirin was not associated with lung cancer (> 3 days/week vs. none, HR 1.09,
95% CI, 0.87–1.37, P for trend 0.52), whereas specific types of non-aspirin NSAIDs were
associated with a small, non-significant reductions: ibuprofen (>1.4 days/week vs. none, HR
0.87, 95% CI, 0.65–1.17, P for trend 0.18), naproxen (>1.2 days/week vs. none, HR 0.71, 95%
CI, 0.44–1.13, P for trend 0.24), and selective COX-2 inhibitors (any use compared to no use,
HR 0.91, 95% CI, 0.74–1.11, P 0.35).
The most frequent use of total NSAIDs was associated with a reduced incidence of NSCLC
(Table 2). Results were similar for both the non-aspirin NSAID and regular aspirin use with
NSCLC, but did not reach statistical significance (data not shown). When NSCLC was
stratified into subtypes, the risk reduction associated with total NSAID use was strongest for
adenocarcinoma and NSCLC, NOS (Table 2). Total NSAID use, non-aspirin NSAID use, and
regular aspirin use were neither associated with small cell lung cancers nor with the “other”
morphology category. Low-dose aspirin use and selective COX-2 inhibitor use were also not
associated with any morphology of incident lung cancer (data not shown).
There was evidence of effect modification by sex for total NSAID use (P for interaction =0.05)
(Table 3). For men, frequent total NSAID use was associated with a decreased risk of lung
cancer that was not seen for women. Of note, there was no evidence for effect modification by
sex for adenocarcinoma (P for interaction = 0.65). More frequent total NSAID use was
associated with reduced risk for adenocarcinoma in both men and women: (men: 3rd tertile vs.
none, HR 0.51, 95% CI, 0.26–1.00, P for trend 0.03; women: 3rd tertile vs. none, HR 0.68,
95% CI, 0.36–1.27, P for trend 0.12)..
There was no appreciable effect modification by smoking status for total NSAID use (P for
interaction = 0.22) though the only significant association was for subjects who had quit
smoking ten or more years prior to baseline (Table 3).
Discussion
In this study, frequency of total long-term NSAID use (excluding low-dose aspirin) was
associated with a borderline inverse association with incident lung cancer. Frequent use of total
NSAIDs was associated with a significant 30–40% decreased incidence of NSCLC and
adenocarcinoma. There was no clear difference by type of NSAID. There was evidence for
effect modification by sex, as total NSAID use was significantly associated with a decreased
risk for total lung cancer for men but not for women.
Our results are consistent with the meta-analysis of the association between NSAIDs and lung
cancer that was strongest for 36 months or more of use (10). Our analysis has several advantages
in that it is a large, prospective cohort of both sexes. We extensively evaluated smoking
behaviors and other potential confounding factors, including indications for NSAID use, and
modeled long-term NSAID use in a dose-response fashion. We evaluated the association of
NSAID use with specific lung cancer morphologies to explore the underlying biologic
mechanisms.
Lung adenocarcinoma may be the predominant morphology affected by NSAIDs. COX-2 is
expressed at greater levels in lung adenocarcinoma compared to other histologies (3,4,13) and
it is overexpressed in pre-malignant atypical adenomatous hyperplasia (14). COX-2
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overexpression has been found to be associated with expression of the proliferation marker
Ki-67 in adenocarcinoma but not squamous cell carcinoma (15) and a trial of subjects at risk
of lung cancer given the selective COX-2 inhibitor celecoxib showed decreased levels of this
same proliferation marker in bronchial biopsies (16). The observed association between total
NSAID use and a decreased risk of adenocarcinoma adds to this evidence.
There was no clear evidence of effect modification by smoking status but there was evidence
for a gender difference. A meta-analysis did not show a gender difference though the combined
odds ratio was not significant for women (10). Recent studies limited to women have had
conflicting results; the Iowa Women’s Health Study did not show an association with either
aspirin or non-aspirin NSAIDs with incident lung cancer (17) though a recent case-control
analysis found a protective association (18). A lung cancer pathogenesis model showed that
estradiol increased COX-2 production (19), which could lead to a potentiation of NSAIDs
inhibitory effect on COX-2. In addition, given that COX-2 is associated with the production
of aromatase (20,21), which is critical for estrogen production, it may be that the effects of
COX-2 inhibition may differ according to background estrogen production.
Despite the biologic plausibility of our results, there are several potential limitations. First,
residual confounding may be a factor. We were unable to adjust for environmental tobacco
exposure or occupational exposures. Second, the measurement of long-term use of NSAIDs is
based on recall and did not include pills per day; each of these issues may attenuate our results.
Third, the VITAL cohort was predominantly white and includes fewer current smokers than
the overall proportion of the U.S. as whole, limiting generalizability.
In conclusion, we found that long-term, frequent use of total non-steroidal anti-inflammatory
drugs was associated with a decreased incidence of lung cancer with the strongest evidence
for a protective association with adenocarcinoma. While we cannot exclude the possibility of
residual confounding, our study was able to adjust for many confounders, most importantly
smoking variables and health conditions associated with NSAID use. Importantly, the results
are in agreement with underlying biological mechanisms of the COX-2 pathway and lung
adenocarcinoma. While our results are promising, the known risks and benefits for current and
former smokers of the various COX-2 inhibitor NSAIDs must be evaluated before they should
be recommended as chemoprevention agents for lung cancer.
References
1. Ries LAG, MD.; Krapcho, M.; Mariotto, A.; Miller, BA.; Feuer, EJ.; Clegg, L.; Horner, MJ.; Howlader,
N.; Eisner, MP.; Reichman, M.; Edwards, BK., editors. SEER Cancer Statistics Review, 1975–2004.
Bethesda, MD: National Cancer Institute; 2008. http://seer.cancer.gov/csr/1975_2005/, based on
November 2007 SEER data submission, posted to the SEER web site, 2008
2. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former
smokers. J Natl Cancer Inst 1993;85:457–64. [PubMed: 8445673]
3. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM. Inflammation in lung
carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol
2008;66:208–17. [PubMed: 18304833]
4. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in
human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761–4. [PubMed:
9731479]
5. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-
inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review).
Oncol Rep 2005;13:559–83. [PubMed: 15756426]
6. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem
2007;42:93–126. [PubMed: 17612047]
Slatore et al. Page 5













7. Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA Jr. Chemoprevention of lung
cancer--from biology to clinical reality. Ann Oncol 2004;15:185–96. [PubMed: 14760107]
8. Sandler AB, Dubinett SM. COX-2 inhibition and lung cancer. Semin Oncol 2004;31:45–52. [PubMed:
15179623]
9. Riedl K, Krysan K, Pold M, et al. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist
Updat 2004;7:169–84. [PubMed: 15296859]
10. Khuder SA, Herial NA, Mutgi AB, Federman DJ. Nonsteroidal antiinflammatory drug use and lung
cancer: a metaanalysis. Chest 2005;127:748–54. [PubMed: 15764753]
11. White E, Patterson RE, Kristal AR, et al. VITamins And Lifestyle cohort study: study design and
characteristics of supplement users. Am J Epidemiol 2004;159:83–93. [PubMed: 14693663]
12. Slatore CG, Littman AJ, Au DH, Satia JA, White E. Long-term use of supplemental multivitamins,
vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. Am J Respir Crit Care Med
2008;177:524–30. [PubMed: 17989343]
13. Xing L, Zhang Z, Xu Y, Zhang H, Liu J. Expression and significance of cyclooxygenase 2 gene in
lung cancer. J Huazhong Univ Sci Technolog Med Sci 2004;24:326–8. [PubMed: 15587390]
14. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs
frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000;30:73–81.
[PubMed: 11086200]
15. Tsubochi H, Sato N, Hiyama M, et al. Combined analysis of cyclooxygenase-2 expression with p53
and Ki-67 in nonsmall cell lung cancer. Ann Thorac Surg 2006;82:1198–204. [PubMed: 16996907]
16. Mao JT, Fishbein MC, Adams B, et al. Celecoxib decreases Ki-67 proliferative index in active
smokers. Clin Cancer Res 2006;12:314–20. [PubMed: 16397057]
17. Hayes JH, Anderson KE, Folsom AR. Association between nonsteroidal anti-inflammatory drug use
and the incidence of lung cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers
Prev 2006;15:2226–31. [PubMed: 17119050]
18. Van Dyke AL, Cote ML, Prysak G, Claeys GB, Wenzlaff AS, Schwartz AG. Regular Adult Aspirin
Use Decreases the Risk of Non-Small Cell Lung Cancer among Women. Cancer Epidemiol
Biomarkers Prev 2008;17:148–57. [PubMed: 18187393]
19. Ho CC, Ling YC, Chang LW, Tsai HT, Tsai MH, Lin P. 17-Beta estradiol and hydroxyestradiols
interact via the NF-kappa B pathway to elevate cyclooxygenase 2 expression and prostaglandin E2
secretion in human bronchial epithelial cells. Toxicol Sci 2008;104:294–302. [PubMed: 18480072]
20. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor
is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase)
gene. Endocrinology 1996;137:5739–42. [PubMed: 8940410]
21. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of
aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett
1999;140:27–35. [PubMed: 10403538]
Slatore et al. Page 6

























Slatore et al. Page 7
Table 1
Hazard Ratios for Lung Cancer Associated with Ten Year Average Use of Non-











 None 51.9% 50.9% Referent
 1st Tertile (0.4–1.4 days/week) 18.1% 17.9% 0.94 (0.75–1.18)
 2nd Tertile (>1.4–4.2 days/week) 17.1% 16.2% 0.83 (0.66–1.05)
 3rd Tertile (>4.2 days/week) 13.0% 15.0% 0.82 (0.64–1.04)
  P for trend§ 0.05
Non-Aspirin NSAID Use||
 None 67.8% 71.3% Referent
 1st Tertile (0.4–1.19 days/week) 9.3% 8.8% 0.88 0.65–1.18
 2nd Tertile (1.2–2.2 days/week) 12.9% 11.1% 0.89 0.68–1.16
 3rd Tertile (> 2.2 days/week) 10.0% 8.8% 0.81 0.60–1.09
  P for trend§ 0.12
Regular Aspirin Use**
 None 75.4% 70.7% Referent
 1st Tertile (0.4–1.4 days/week) 8.6% 10.1% 1.16 0.89–1.53
 2nd Tertile (>1.4–3.0 days/week) 5.5% 4.3% 0.77 0.51–1.15
 3rd Tertile (> 3.0 days/week) 10.5% 14.9% 0.90 0.71–1.15
  P for trend§ 0.31
*
Percentages are of non-missing data though may not add to 100% secondary to rounding. No subjects were missing age or gender information. 769
(1.0%) and 916 (1.1%) of subjects were missing information on years smoked and packyears, respectively. 4000 subjects (5.2%) of subjects were missing
information on acetaminophen use.
†
All adjusted for age, sex, years smoked, packyears, packyears squared, and acetaminophen use; non-aspirin NSAID use also adjusted for regular aspirin
use and regular aspirin use also adjusted for total non-aspirin NSAID use
‡
Includes aspirin, ibuprofen, naproxen, celecoxib, rofecoxib, and other pain relievers such as indomethacin and piroxicam (last category for women only)
but excludes low-dose aspirin use. 6.0% of subjects missing this datum.
§
P values for trend across ordered categories
||
Includes ibuprofen, naproxen, celecoxib, rofecoxib, and other pain relievers such as indomethacin and piroxicam (last category for women only). 7.4%
of subjects missing this datum.
**
Excludes low-dose aspirin use. 4.9% of subjects missing this datum.
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Table 2
Hazard Ratios for Different Morphologies of Lung Cancer Associated with Ten Year Average Use of Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs).
Morphology







3rd Tertile >4.2 days/
week
NSCLC (501 cases)§ 0.89 (0.68–1.15) 0.85 (0.65–1.10) 0.68 (0.51–0.92) 0.01
Adenocarcinoma 226 cases 1.03 (0.72–1.47) 0.69 (0.45–1.05) 0.59 (0.37–0.94) 0.01
Squamous Cell 116 cases 0.62 (0.33–1.16) 1.01 (0.60–1.70) 0.97 (0.57–1.64) 0.95
NSCLC, NOS 143 cases 0.89 (0.55–1.45) 0.88 (0.55–1.43) 0.57 (0.32–1.01) 0.06
SCLC (90 cases) 1.51 (0.84–2.69) 0.66 (0.30–1.44) 1.43 (0.80–2.57) 0.57
Abbreviations: NSCLC: Non-small cell lung cancer; SCLC: Small Cell Lung Cancer; NOS: not otherwise specified
*
All HR’s use the “No Use” category as the referent. All HR’s adjusted for age, sex, years smoked, packyears, packyears squared, and acetaminophen
use
†
Includes aspirin, ibuprofen, naproxen, celecoxib, rofecoxib, and other pain relievers such as indomethacin and piroxicam (last category for women only)
but excludes low-dose aspirin use
‡
P values for trend measured ordered categorically
§
Subset of NSCLC cases do not sum to 501 secondary to 16 cases of large cell carcinoma not included in this analysis
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Table 3
Hazard Ratios for Lung Cancer for Subgroups based on Sex and Smoking Status
Associated with Ten Year Average Use of Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs)
Subgroup
Adjusted Hazard Ratios (95% CI)*
P for trend‡
Total NSAID Use†




3rd Tertile >4.2 days/
week
Sex
 Women 0.90 (0.64–1.27) 0.92 (0.66–1.30) 1.07 (0.75–1.51) 0.91
 Men 0.98 (0.73–1.32) 0.76 (0.55–1.06) 0.66 (0.47–0.92) 0.01
  P for Interaction 0.05
Smoking Status
 Former, quit ≥ 10yrs 0.79 (0.55–1.14) 0.88 (0.62–1.25) 0.65 (0.44–0.96) 0.04
 Former, quit <10 yrs 1.40 (0.88–2.21) 0.61 (0.33–1.13) 0.97 (0.56–1.68) 0.46
 Current 0.76 (0.49–1.17) 0.79 (0.51–1.22) 1.02 (0.68–1.52) 0.74
  P for Interaction 0.22
*
All HR’s use the “No Use” category as the referent. All HR’s adjusted for age, years smoked, packyears, packyears squared, and acetaminophen use.
HR’s for smoking status also adjusted for sex.
†
Includes ibuprofen, naproxen, celecoxib, rofecoxib, and other pain relievers such as indomethacin and piroxicam (last category for women only)
‡
P values for trend measured ordered categorically
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